Patents by Inventor James Guy Breitenbucher

James Guy Breitenbucher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydro-pyrimidoazepines as modulators of TRPV1
    Patent number: 8673895
    Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: March 18, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bryan James Branstetter, James Guy Breitenbucher, Natalie A. Hawryluk, Alec D. Lebsack, Jeffrey E. Merit
  • Quinoline or isoquinoline substituted P2X7 antagonists
    Patent number: 8431704
    Abstract: The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. (I).
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: April 30, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Christopher John Love, Joseph Elisabeth Leenaerts, Ludwig Paul Cooymans, Donald Alec Lebsack, Bryan James Branstetter, Jason Christopher Rech, Elizabeth Ann Gleason, Jennifer Diane Venable, Danielle Wiener, Deborah Margaret Smith, James Guy Breitenbucher
  • QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS
    Publication number: 20110092481
    Abstract: The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Application
    Filed: April 21, 2009
    Publication date: April 21, 2011
    Inventors: Christopher John Love, Joseph Elisabeth Leenaerts, Ludwig Paul Cooymans, Donald Alec Labsack, Bryan James Branstetter, Jason Christopher Rech, Elizabeth Ann Gleason, Jennifer Diane Venable, Danielle Wiener, Deborah Margaret Smith, James Guy Breitenbucher
  • Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase
    Publication number: 20100292266
    Abstract: Certain oxazolyl piperidine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
    Type: Application
    Filed: May 25, 2007
    Publication date: November 18, 2010
    Inventors: Richard Apodaca, James Guy Breitenbucher, Alison L. Chambers, Mark Seierstad, Wei Xiao
  • Thiazolopyrimidine modulators of TRPV1
    Publication number: 20080004253
    Abstract: Certain TRPV1-modulating thiazolopyrimidine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.
    Type: Application
    Filed: June 28, 2007
    Publication date: January 3, 2008
    Inventors: Bryan James Branstetter, James Guy Breitenbucher, Alec D. Lebsack, Wei Xiao
  • Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists
    Patent number: 6596724
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of oxadiazole, thiadiazole and thiadiazole oxide derivatives of dihydropyridines of Formula I. wherein B is with X being O, S or and X1 is O or S. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: July 22, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Mendi Higgins, James Guy Breitenbucher
  • Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists
    Publication number: 20020013323
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of oxadiazole, thiadiazole and thiadiazole oxide derivatives of dihydropyridines of Formula I.
    Type: Application
    Filed: July 2, 2001
    Publication date: January 31, 2002
    Inventors: Graham S. Poindexter, Mendi Higgins, James Guy Breitenbucher
  • Dihydropyridine NPY antagonists: cyanoguanidine derivatives
    Patent number: 6001836
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of cyanoguanidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). ##STR1## As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: December 14, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, R. Thomas Swann, Marc A. Bruce, Mendi A. Morton, Yazhong Huang, Sing-Yuen Sit, James Guy Breitenbucher